New pill shows promise in slowing lung scarring disease
Disease control
Ongoing
This study tests a new oral drug called buloxibutid in 378 adults with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs and makes breathing hard. Over 52 weeks, researchers compare two doses of the drug against a placebo to see if it helps maintain lung functio…
Phase: PHASE2 • Sponsor: Vicore Pharma AB • Aim: Disease control
Last updated May 17, 2026 19:10 UTC